Logo

OPRX

OptimizeRx Corporation

OPRX

OptimizeRx Corporation • NASDAQ
$15.27 ▼ -0.72% (-0.11)
Market Cap $282.41 M
52w High $22.25
52w Low $3.99
Dividend Yield 0%
P/E 1527
Volume 80.19K
Outstanding Shares 18.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $26.067M ▼ $15.466M ▲ $779K ▼ 2.988% ▼ $0.04 ▼ $3.144M ▼
Q2-2025 $29.195M ▲ $15.446M ▼ $1.532M ▲ 5.247% ▲ $0.083 ▲ $4.39M ▲
Q1-2025 $21.928M ▼ $15.458M ▼ $-2.199M ▼ -10.028% ▼ $-0.12 ▼ $-893K ▼
Q4-2024 $32.316M ▲ $18.389M ▼ $-78K ▲ -0.241% ▲ $0 ▲ $4.865M ▲
Q3-2024 $21.309M $22.009M $-9.124M -42.818% $-0.5 $-7.322M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $19.519M ▲ $170.321M ▲ $48.058M ▼ $122.263M ▲
Q2-2025 $16.585M ▲ $169.265M ▲ $49.981M ▼ $119.284M ▲
Q1-2025 $16.573M ▲ $167.768M ▼ $51.498M ▼ $116.27M ▼
Q4-2024 $13.38M ▼ $171.168M ▲ $54.17M ▲ $116.998M ▲
Q3-2024 $16.126M $165.199M $50.734M $114.465M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $779K ▼ $3.202M ▼ $-10K ▲ $-258K ▲ $2.934M ▲ $3.192M ▼
Q2-2025 $1.532M ▲ $4.561M ▲ $-44K ▲ $-4.505M ▼ $12K ▼ $4.551M ▲
Q1-2025 $-2.199M ▼ $3.864M ▲ $-84K ▲ $-587K ▲ $3.193M ▲ $3.837M ▲
Q4-2024 $-79K ▲ $198K ▼ $-120K ▼ $-2.824M ▼ $-2.746M ▼ $78K ▼
Q3-2024 $-9.124M $1.791M $-92K $-532K $1.167M $1.699M

Five-Year Company Overview

Income Statement

Income Statement Revenue has risen steadily over the past several years, showing that demand for OptimizeRx’s digital health and pharma communication solutions is growing. Gross profit has expanded broadly in line with sales, which suggests the core business model can scale, but operating costs have grown faster than revenue. As a result, operating profit and net income have hovered around break‑even or modest losses, with a brief period of small profitability followed by a return to the red. The most recent year shows some improvement in operating results versus the prior year, but the company is still not consistently profitable, reflecting ongoing investment and the drag from the transition in its business model.

Balance Sheet

Balance Sheet The balance sheet has grown over time, with total assets and shareholder equity both increasing, which indicates cumulative investment and value creation rather than heavy erosion of capital. However, the cash balance is now relatively modest compared with its earlier peak, suggesting that the company has drawn down liquidity as it has invested in growth and acquisitions. Debt was essentially absent until recently and has now appeared at a moderate level, which slightly increases financial risk but still leaves the company far from being highly leveraged. Overall, OptimizeRx has a reasonable equity cushion but a thinner cash buffer than in the past, so careful working‑capital and capital‑allocation management will matter.

Cash Flow

Cash Flow Cash generation from day‑to‑day operations has been inconsistent, oscillating around break‑even rather than providing a steady surplus. Free cash flow largely mirrors this pattern, as capital spending is very low, consistent with an asset‑light, software‑driven model. This means the business does not require heavy investment in physical assets, but it also has not yet demonstrated a reliable ability to turn its growing revenue into durable cash inflows. The cash‑flow profile fits a company still in the investment and scaling phase rather than one in a mature, cash‑harvesting stage, and it leaves less room for error if growth slows or costs surprise on the upside.

Competitive Edge

Competitive Edge OptimizeRx operates in a specialized corner of digital health, sitting at the intersection of pharmaceutical marketing, real‑world data, and electronic health records. Its deep integrations across hundreds of EHR systems and access to a very large base of healthcare providers give it a meaningful network advantage that would be time‑consuming and costly for new entrants to replicate. The platform gains strength as more life‑science clients and clinicians join, creating data and relationship “stickiness” and raising switching costs for existing customers. At the same time, the company competes in a dynamic space with other digital health and data‑driven marketing platforms, and it remains dependent on pharmaceutical promotional budgets and evolving healthcare regulations, which can both support or constrain growth over time.

Innovation and R&D

Innovation and R&D The company’s strategy leans heavily on innovation, particularly around its AI‑driven Dynamic Audience Activation Platform and related tools that target messages to clinicians and patients with high precision. Proprietary capabilities like Micro‑Neighborhood audience building and therapy‑initiation and persistence solutions move the offering beyond simple advertising into clinical‑workflow support and adherence improvement. Integration of real‑world data, HIPAA‑compliant text engagement, and digital field‑force connectivity create a differentiated, end‑to‑end communication ecosystem. The shift toward subscription‑based offerings and expansion into high‑value specialties and omnichannel campaigns, aided by the Medicx acquisition, suggest ongoing and substantial investment in product development and data science, which supports the moat but also weighs on near‑term margins.

Summary

OptimizeRx is a growing, data‑rich digital health platform with a strong strategic position at the point of care and a clear focus on AI‑enabled, high‑precision engagement for pharma, providers, and patients. The business shows healthy top‑line momentum and attractive gross economics but remains in a transition phase where profitability and cash generation are not yet consistently established. Its integrated EHR network, proprietary data, and expanding suite of solutions give it a credible competitive moat, but also expose it to cyclical pharma marketing budgets, regulatory shifts, and ongoing technology competition. Progress on stabilizing margins, growing recurring subscription revenue, and rebuilding its cash cushion—while continuing to innovate—will be key markers of how the risk‑reward profile evolves from here.

NEWS

November 6, 2025 · 4:01 PM UTC

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

Read more

October 20, 2025 · 8:00 AM UTC

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET

Read more

September 10, 2025 · 7:30 AM UTC

OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference

Read more

September 9, 2025 · 4:05 PM UTC

OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

Read more